[go: up one dir, main page]

NO972091L - Bestemte substituerte benzylaminderivater; en ny klasse nouropeptid-yl-spesifikke ligander - Google Patents

Bestemte substituerte benzylaminderivater; en ny klasse nouropeptid-yl-spesifikke ligander

Info

Publication number
NO972091L
NO972091L NO972091A NO972091A NO972091L NO 972091 L NO972091 L NO 972091L NO 972091 A NO972091 A NO 972091A NO 972091 A NO972091 A NO 972091A NO 972091 L NO972091 L NO 972091L
Authority
NO
Norway
Prior art keywords
nouropeptide
new class
specific ligands
certain substituted
substituted benzylamine
Prior art date
Application number
NO972091A
Other languages
English (en)
Other versions
NO972091D0 (no
Inventor
John M Peterson
Charles A Blum
Guolin Cai
Alan Hutchison
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO972091D0 publication Critical patent/NO972091D0/no
Publication of NO972091L publication Critical patent/NO972091L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Oppfinnelsen omfatter forbindelser med formel (I) og de farmasøytiske akseptable salter derav, hvori W, X, Y, A og T representerer organiske eller uorganiske substituenter, n er 1, 2 eller 3, m er 2, 3 eller 4 R-Rer hydrogen eller organiske substituenter, og B er nitrogen, karbon, svovel eller oksygen, anvendelige ved diagnosebehandling av spiseforstyrrelser så som fedme og bulimi og kardiovaskulære sykdommer så som essensiell hypertensjon og kongestiv hjertesvikt på grunn av bindingen til disse forbindelsene til neuropeptid. Y1 humanreseptorer.
NO972091A 1994-11-07 1997-05-06 Bestemte substituerte benzylaminderivater; en ny klasse nouropeptid-yl-spesifikke ligander NO972091L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US33547594A 1994-11-07 1994-11-07
US48497495A 1995-06-07 1995-06-07
US47438395A 1995-06-07 1995-06-07
PCT/US1995/014472 WO1996014307A1 (en) 1994-11-07 1995-11-07 Certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands

Publications (2)

Publication Number Publication Date
NO972091D0 NO972091D0 (no) 1997-05-06
NO972091L true NO972091L (no) 1997-07-02

Family

ID=27407057

Family Applications (1)

Application Number Title Priority Date Filing Date
NO972091A NO972091L (no) 1994-11-07 1997-05-06 Bestemte substituerte benzylaminderivater; en ny klasse nouropeptid-yl-spesifikke ligander

Country Status (12)

Country Link
JP (1) JP3386814B2 (no)
KR (1) KR970707101A (no)
AU (1) AU692977B2 (no)
BR (1) BR9509610A (no)
CA (1) CA2203878C (no)
CZ (1) CZ137297A3 (no)
HU (1) HUT78089A (no)
NO (1) NO972091L (no)
NZ (1) NZ297211A (no)
PL (1) PL321136A1 (no)
SK (1) SK57097A3 (no)
WO (1) WO1996014307A1 (no)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602024A (en) 1994-12-02 1997-02-11 Synaptic Pharmaceutical Corporation DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
US5989920A (en) 1994-12-02 1999-11-23 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior compounds useful in such methods and DNA encoding a hypothalmic atypical neuropeptide Y/peptide YY receptor Y5
ATE230403T1 (de) * 1996-07-23 2003-01-15 Neurogen Corp Einige amido- und ammo- substituierte benzylaminderivate: eine neue klasse von neuropeptid y1 spezifische ligande
CA2268051A1 (en) 1996-08-23 1998-02-26 Alanex Corporation Neuropeptide-y ligands
FR2754709B1 (fr) 1996-10-23 1999-03-05 Sanofi Sa Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition
PA8441701A1 (es) * 1996-11-26 2000-05-24 Pfizer Sales dimesilato de los ligandos del neuropeptido y
US6245817B1 (en) 1997-02-14 2001-06-12 Bayer Corporation NPY5 receptor antagonists and methods for using same
JP2000510164A (ja) * 1997-02-14 2000-08-08 バイエル・コーポレーシヨン 選択的神経ペプチドｙ受容体アンタゴニストとしてのアミド誘導体
US6048900A (en) 1998-02-13 2000-04-11 Bayer Corporation Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists
US6713265B1 (en) 1997-06-04 2004-03-30 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)
US5889016A (en) * 1997-06-26 1999-03-30 Bristol-Myers Squibb Company Dihydropyrimidone derivatives as NPY antagonists
ID24300A (id) 1997-08-05 2000-07-13 Pfizer Prod Inc 4-AMINOPIROL(3,2-d)PIRIMIDIN SEBAGAI ANTAGONIS-ANTAGONIS RESEPTOR NEUROPEPTIDA Y
EP0896822B1 (en) * 1997-08-05 2003-03-12 Pfizer Products Inc. 4-Aminopyrrole (3,2-d) pyrimidines as neuropeptide Y receptor antagonists
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
DK1027891T3 (da) 1999-01-27 2005-05-09 Pfizer Prod Inc Neuropeptid-Y-antagonister
AU2935200A (en) 1999-04-30 2000-11-17 Pfizer Products Inc. Compounds for the treatment of obesity
AU778393B2 (en) 1999-05-12 2004-12-02 Ortho-Mcneil Pharmaceutical, Inc. Pyrazole carboxamides useful for the treatment of obesity and other disorders
CA2377698A1 (en) 1999-06-21 2000-12-28 Bristol-Myers Squibb Company Dihydropyrazine derivatives as npy antagonists
US6531478B2 (en) 2000-02-24 2003-03-11 Cheryl P. Kordik Amino pyrazole derivatives useful for the treatment of obesity and other disorders
JP2004516239A (ja) 2000-07-06 2004-06-03 ニューロジェン コーポレイション メラニン凝集ホルモン受容体リガンド
EP1935885A3 (en) * 2001-05-22 2008-10-15 Neurogen Corporation Melanin concentrating hormone receptor ligands : substituted 1-benzyl-4-aryl piperazine analogues.
US6953801B2 (en) * 2001-05-22 2005-10-11 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
DE10213051B4 (de) 2002-03-23 2013-03-07 Grünenthal GmbH Substituierte 4-Aminocyclohexanole
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
AU2004266233A1 (en) 2003-08-13 2005-03-03 Amgen, Inc. Melanin concentrating hormone receptor antagonist
ATE547404T1 (de) 2003-09-22 2012-03-15 Msd Kk Piperidinderivate
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
EP2286837A3 (en) 2004-11-01 2013-09-04 Amylin Pharmaceuticals, LLC Treatment of obesity and obesity related diseases
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
NZ562766A (en) 2005-05-30 2011-03-31 Banyu Pharma Co Ltd Piperidine derivatives as histamine-H3 receptor antagonists
US20100216758A1 (en) 2005-08-10 2010-08-26 Makoto Ando Pyridone Compounds
EP2330125A3 (en) 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
AU2006279680B2 (en) 2005-08-11 2012-12-06 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
AU2006282260A1 (en) 2005-08-24 2007-03-01 Msd K.K. Phenylpyridone derivative
EP1939194A4 (en) 2005-09-07 2010-12-08 Banyu Pharma Co Ltd BICYCLIC AROMATIC SUBSTITUTED PYRIDONE DERIVATIVE
CN101277960A (zh) 2005-09-29 2008-10-01 默克公司 作为黑皮质素-4受体调节剂的酰化螺哌啶衍生物
WO2007048027A2 (en) 2005-10-21 2007-04-26 Novartis Ag Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
CA2627139A1 (en) 2005-10-27 2007-05-03 Banyu Pharmaceutical Co., Ltd. Novel benzoxathiin derivative
WO2007055418A1 (ja) 2005-11-10 2007-05-18 Banyu Pharmaceutical Co., Ltd. アザ置換スピロ誘導体
EP2698157B1 (en) 2006-09-22 2015-05-20 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
AU2007301126A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JPWO2009110510A1 (ja) 2008-03-06 2011-07-14 Ｍｓｄ株式会社 アルキルアミノピリジン誘導体
US20110015198A1 (en) 2008-03-28 2011-01-20 Banyu Pharmaceutical Co., Inc. Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2727914A1 (en) 2008-06-19 2009-12-23 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diaryl ketoxime derivative technical field
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2319841A1 (en) 2008-07-30 2011-05-11 Msd K.K. (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
AU2009308980B2 (en) 2008-10-30 2013-02-28 Merck Sharp & Dohme Corp. Isonicotinamide orexin receptor antagonists
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
WO2010075068A1 (en) 2008-12-16 2010-07-01 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
BR112013021236B1 (pt) 2011-02-25 2021-05-25 Merck Sharp & Dohme Corp composto derivado de benzimidazol, e, composição
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
US9527875B2 (en) 2012-08-02 2016-12-27 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
MX2015010935A (es) 2013-02-22 2015-10-29 Merck Sharp & Dohme Compuestos biciclicos antidiabeticos.
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014274812B2 (en) 2013-06-05 2018-09-27 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase C, method of making and using same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
DK3186242T3 (da) 2014-08-29 2021-12-20 Tes Pharma S R L Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
AR109950A1 (es) 2016-10-14 2019-02-06 Tes Pharma S R L INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
BR112021009589A2 (pt) 2018-11-20 2021-08-17 Tes Pharma S.R.L. inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
US11098029B2 (en) 2019-02-13 2021-08-24 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
US12331018B2 (en) 2019-02-13 2025-06-17 Merck Sharp & Dohme Llc Pyrrolidine orexin receptor agonists
AU2020256166A1 (en) 2019-04-02 2021-10-14 Aligos Therapeutics, Inc. Compounds targeting PRMT5
WO2021026047A1 (en) 2019-08-08 2021-02-11 Merck Sharp & Dohme Corp. Heteroaryl pyrrolidine and piperidine orexin receptor agonists
MX2023001840A (es) 2020-08-18 2023-03-13 Merck Sharp & Dohme Llc Agonistas de bicicloheptano pirrolidina de los receptores de orexina.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4845221A (en) 1988-04-15 1989-07-04 American Home Products Corporation Serotonergic substituted piperazinyl tetralins
DD297968A5 (de) * 1989-04-22 1992-01-30 �����@��������@�K@�����������@�������k�� Neue piperazine, ihre herstellung und verwendung in pharmazeutischen mitteln

Also Published As

Publication number Publication date
PL321136A1 (en) 1997-11-24
KR970707101A (ko) 1997-12-01
JP3386814B2 (ja) 2003-03-17
NO972091D0 (no) 1997-05-06
JP2001520625A (ja) 2001-10-30
AU4231996A (en) 1996-05-31
AU692977B2 (en) 1998-06-18
SK57097A3 (en) 1998-10-07
MX9703349A (es) 1997-07-31
HUT78089A (hu) 1999-08-30
CA2203878A1 (en) 1996-05-17
CA2203878C (en) 2002-06-25
WO1996014307A1 (en) 1996-05-17
NZ297211A (en) 1999-01-28
BR9509610A (pt) 1997-10-28
CZ137297A3 (cs) 1998-04-15

Similar Documents

Publication Publication Date Title
NO972091L (no) Bestemte substituerte benzylaminderivater; en ny klasse nouropeptid-yl-spesifikke ligander
DK0915859T3 (da) Visse substituerede benzylaminderivater; en ny klasse af Neuropeptid Y1-specifikke ligander
DK0773226T3 (da) Propiophenonderivater og fremgangsmåder til fremstilling deraf
NO902262L (no) Fremgangsmaate for fremstilling av azainden-derivater.
NZ513639A (en) Cyclic protein tyrosine kinase inhibitors
NO971520L (no) Fremgangsmåte for hemming av tilstander forbundet med neuropeptid Y
ATE242213T1 (de) Neue 4-(oxyalkoxyphenyl)-3-oxy-piperidine zur behandlung von herz- und niereninsuffizienz
DK256890A (da) Benzo-piperidin-, -piperidyliden- og piperazinforbindelser, kompositioner indeholdende forbindelserne og fremgangsmaader til forbindelsernes fremstilling og anvendelse
NO20044763L (no) 1-(aminoalkyl)-3-sulfonylazaindoler som 5-hydroksytryptamin-6 ligander
DE69922216D1 (de) Porphyrin derivate, ihre verwendung in der photodynamischen therapie und diese enthaltende medizinische geräte
MY126736A (en) 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof
ATE179706T1 (de) N-heteroaryl-n'-phenylharnstoffderivate, ihre herstellung und verwendung
MX9207392A (es) Alquilo de imidazoil substituido con una cadena heterociclica de seis miembros que contiene nitrogeno.
NZ524742A (en) Bridged piperazine derivatives
ATE121385T1 (de) Harnstoffderivate, ihre herstellung und ihre verwendung bei der therapie.
HUP0102057A2 (hu) Benzofuroxánszármazékok alkalmazása angina pectoris kezelésében
TW242138B (no)
DE60227421D1 (de) Rmazeutische zusammensetzung und verwendung davon
NO904575D0 (no) Benzocykloalkylaminopyridinaminer og beslektede forbindelser, mellomprodukter, fremgangsmaate for deres fremstillingog anvendelse som medikamenter.
DE3775666D1 (de) Hydroxybutenolid-derivate, ihre herstellung und ihre verwendung.
DK662189A (da) Pyridinylcarbazolaminer, deres fremstilling og anvendelse som laegemidler
ATE275572T1 (de) Malto-oligosaccharid-derivate und ihre anwendungen
DK0405342T3 (da) (1,2,3,4-Tetrahydro-9-acridinimino)cyclohexancarboxylsyre og beslægtede forbindelser, en fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler
NO870423D0 (no) 5-substituert octahydroindolizin-analgetika-forbindelser og 7-keto-mellomprodukt.
MX9709980A (es) Ciertos derivados de bencilamina sustituidos: una nueva clase de ligandos especificos del neuropeptido y1.